IRON

Disc Medicine Inc. on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP.

Disc Medicine reported that its pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X linked protoporphyria met all primary and secondary endpoints, including a 41.4% reduction in metal free PPIX and a 12.2 hour gain in pain free…

Disc Medicine (IRON) is back in focus after reporting that its APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria met every primary and secondary goal, reviving attention on the stock.

Disc Medicine (NasdaqGM: IRON) plans to announce topline results from its APOLLO Phase 3 trial of bitopertin in EPP. The firm expects to discuss the Phase 3 APOLLO findings with investors and clinicians as part of the upcoming release.

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the…